Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilent Technologies Inc (A) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance

Agilent Technologies IncTrade
Tencent Music Entertainment Group - ADRTrade

Price performance (Past 24H)

Key statistics

Agilent Technologies Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Tencent Music Entertainment Group - ADR trades at $8.58 (market cap $15.69B). The key difference: Agilent Technologies Inc is far larger — about 2.7× Tencent Music Entertainment Group - ADR's market cap, and Tencent Music Entertainment Group - ADR pays the higher dividend (2.42%). Which is the better fit depends on your goals.

ATME
Market Cap
$42.00B$15.69B
Sector
HealthMedia
52-Week High
$157.20$26.36
52-Week Low
$110.24$8.16
Enterprise Value
$43.55B$12.45B
Dividend Yield
0.69%2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilent Technologies Inc

Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.

The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.

Tencent Music Entertainment Group - ADR

TME trades at $9.53, down 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong 2025 revenue of $32.90B and net income of $11.06B, with a P/E of 11.33 indicating reasonable valuation. Recent news highlights institutional buying and strategic moves like the Ximalaya acquisition to bolster ecosystem dominance.

Outlook is cautiously optimistic with a consensus price target of $14.00, offering 47% upside. Risks include competitive pressures and AI-driven copyright challenges, but solid profitability and Tencent backing provide resilience. The stock presents a value opportunity if execution on premiumization continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Agilent Technologies Inc

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.

Read more on A

About Tencent Music Entertainment Group - ADR

TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.

Read more on TME